-
1 Comment
CanSino Biologics Inc is currently in a long term uptrend where the price is trading 32.2% above its 200 day moving average.
From a valuation standpoint, the stock is 2863.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3335.1.
CanSino Biologics Inc's total revenue rose by 95.2% to $19M since the same quarter in the previous year.
Its net income has dropped by 238.1% to $-294M since the same quarter in the previous year.
Finally, its free cash flow fell by 6.5% to $-306M since the same quarter in the previous year.
Based on the above factors, CanSino Biologics Inc gets an overall score of 2/5.
| Industry | Drug Manufacturers-Specialty & Generic |
|---|---|
| ISIN | CNE100003F01 |
| CurrencyCode | HKD |
| Exchange | HK |
| Sector | Healthcare |
| Dividend Yield | 2.1% |
|---|---|
| Market Cap | 21B |
| Target Price | 118.06 |
| PE Ratio | 9.57 |
| Beta | 0.62 |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 6185.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
